These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 5376451)

  • 41. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
    Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
    Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
    Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In focus: (166) Ho-DOTMP in the pretransplant treatment of multiple myeloma.
    Clapp K
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):753-4. PubMed ID: 16170894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple myeloma: a therapeutic enigma.
    Hoogstraten B
    Am J Clin Oncol; 1982 Feb; 5(1):13-9. PubMed ID: 7081135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J
    Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
    Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
    Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in the treatment of elderly patients with multiple myeloma.
    Facon T
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):501-2. PubMed ID: 17147234
    [No Abstract]   [Full Text] [Related]  

  • 48. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
    Dimopoulos MA; Anagnostopoulos A; Terpos E; Repoussis P; Zomas A; Katodritou E; Kyrtsonis MC; Delibasi S; Vassou A; Pouli A; Zervas K; Anagnostopoulos N; Maniatis A;
    Haematologica; 2006 Feb; 91(2):252-4. PubMed ID: 16461313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
    Hernández JM; García-Sanz R; Golvano E; Bladé J; Fernandez-Calvo J; Trujillo J; Soler JA; Gardella S; Carbonell F; Mateo G; San Miguel JF
    Br J Haematol; 2004 Oct; 127(2):159-64. PubMed ID: 15461621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.
    Bosanquet AG; Gilby ED
    Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of multiple myeloma in patients with Gaucher disease.
    Machaczka M; Lerner R; Klimkowska M; Hägglund H
    Am J Hematol; 2009 Oct; 84(10):694-6. PubMed ID: 19743447
    [No Abstract]   [Full Text] [Related]  

  • 52. Acute leukemia secondary to multiple myeloma.
    de Gramont A; Rioux E; Shields C
    Can Med Assoc J; 1983 Sep; 129(6):534, 536. PubMed ID: 6576845
    [No Abstract]   [Full Text] [Related]  

  • 53. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [High-dose chemotherapy and bone marrow graft in multiple myeloma: hopes and limits].
    Ravaud P; Fermand JP
    Rev Rhum Ed Fr; 1993 Apr; 60(4):266-8. PubMed ID: 8167622
    [No Abstract]   [Full Text] [Related]  

  • 55. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
    Berenson JR; Yellin O; Woytowitz D; Flam MS; Cartmell A; Patel R; Duvivier H; Nassir Y; Eades B; Abaya CD; Hilger J; Swift RA
    Eur J Haematol; 2009 Jun; 82(6):433-9. PubMed ID: 19226361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Indications for chemotherapy in multiple myeloma].
    Heyll A; Aul C
    Dtsch Med Wochenschr; 1996 May; 121(20):675. PubMed ID: 8635404
    [No Abstract]   [Full Text] [Related]  

  • 57. [Therapy of myelomatosis].
    Rordam P
    Ugeskr Laeger; 1969 Jan; 131(1):15-9. PubMed ID: 5766707
    [No Abstract]   [Full Text] [Related]  

  • 58. Update on recent developments for patients with newly diagnosed multiple myeloma.
    Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
    Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical study on chemotherapy for multiple myeloma. Part III: The disappearance of M-protein in multiple myeloma].
    Adachi T; Hasegawa M; Asano K; Sezaki T; Ishii H; Takahashi I; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):440-7. PubMed ID: 6887544
    [No Abstract]   [Full Text] [Related]  

  • 60. [Change of resistance of erythrocytes to sarcolysine in the process of its use].
    Sysoeva TV
    Farmakol Toksikol; 1969; 32(5):626-8. PubMed ID: 4188942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.